DEVELOPING THE NEXT GENERATION OF MEDICINES THAT TARGET AND ENHANCE THE MICROBIOME Groundwork laid for a future of cultured microbiome therapies targeting specific diseases
INTERVIEW
Associate Professor Sam Forster, CSL Centenary Fellow, Research Group Head
Microbiota and Systems Biology, Hudson Institute of Medical Research
& Team Leader, Australian Microbiome Culture Collection
& Chief Scientific Officer, BiomeBank
Dr Sam Costello,
Co-founder & CEO
BiomeBank
SEGMENT
Filmed in Melbourne and Adelaide | December 2024
Australian Health Journal spoke to Associate Professor Sam Forster, Research Group Head, Microbiota and Systems Biology, Hudson Institute of Medical Research, Team Leader, Australian Microbiome Culture Collection & Chief Scientific Officer, BiomeBank and Dr Sam Costello, Co-Founder and CEO of BiomeBank about the microbiome, partnering and some of the breakthroughs in recent years.
Assoc Prof Forster describes the role of the microbiome, “Every one of us carries thousands of bacteria. Millions of individual cells, and they’re intimately associated with all sorts of sites on our bodies. So our gut is the most common place we think about, but our lungs, our skin, everywhere. Where there’s an interface, the external environment, there’s bacteria and other microbes that actually enable us to interface with the external world. They detect changes and they regulate our immune response.”
This can be really important from a health perspective because they indicate when things are going well, we should have a healthy state or something’s gone wrong, and there is an inflammatory response. This can then be detrimental, or it can help clear a particular condition.
“The microbes we carry are intimately associated with our health.”, says Assoc Prof Forster. He was the founder of the Australian Microbiome Culture Collection at Hudson that now contains over 40,000 bacterial isolates. This provides a resource for further research.
“All of these opportunities are available because we have this vast collection of microbes where we can say this particular combination for you is relevant for this experiment. Taking clinical samples, we then can replicate the host environment using microfluidic organ on-a-chip systems”, says Assoc Prof Forster.
Microbiome therapies involve modifying the body’s microbial communities to improve health. These treatments aim to restore balance to the microbiome, potentially alleviating conditions like inflammatory bowel disease, liver disorders, autoimmune diseases, and certain cancers.
The Hudson Institute of Medical Research and BiomeBank have partnered to advance microbiome-based therapeutics. Their collaboration focuses on identifying key bacteria involved in disease onset and resolution, particularly associated with the gut. By combining their expertise, they aim to develop targeted microbial therapies to treat and prevent diseases by restoring gut microbial ecology.
BiomeBank develops and delivers microbiome therapies. In 2022 BiomeBank was successful in introducing the world’s first approved donor derived microbiome therapy approved in Australia for the treatment of C. Difficile infection.
Through this collaboration, the Hudson Institute and BiomeBank are at the forefront of microbiome research, striving to translate scientific discoveries into effective therapies that can improve patient outcomes.
As Dr Costello states, “We see microbiome therapies evolving in the next few years from predominantly donor derived therapies that are harvested from screened healthy stool donors, towards cultured therapies that can be grown in bioreactors and produced under controlled conditions.”
Assoc Prof Forster has been involved in a number of breakthroughs in culturing previously thought to be unculturable organisms.
-
SAHMRI Celebrates 10 Years of Research
SAHMRI represents an exciting and unique statewide concept, bringing together basic and translational research, South Australia’s three universities and the health system. SAHMRI works in collaboration with its partners to provide a clear focal point for health and medical research, including paving the way for new partnerships, innovative research projects and improved health outcomes.
Executive Director, Professor Maria Makrides spoke to Australian Health Journal about 3 achievements in the past 10 years that have had significant impact
International leadership breakthroughs in leukaemia research
Culturally appropriate Indigenous health research and clinical care
Omega 3 fatty acids as a preterm birth prevention -
Redefining diversity in clinical trials
Ensuring inclusion, diversity, equity and patient input in the development of novel drugs and medical devices has become well accepted in health care. However appropriate implementation of these elements has been a challenge for many. Only by implementing these conscious inputs can patient outcomes be improved and health disparities in marginalised groups be addressed.
Australian Health Journal spoke to Gillian Mason, Consumer and Community Involvement Lead at Hunter Medical Research Institute in Newcastle, NSW on this topic discussed at the recent ARCS Conference in Sydney.
-
Metabolic health expert talks about healthy ageing
David Beard is a highly experienced Exercise Physiologist with a specialisation in metabolic health and healthy aging. He has spent over 40 years in this profession, even before exercise physiology was formally recognised as a discipline. His extensive background includes over a decade of working in aged care and a strong focus on adult health and fitness. David has authored a book on healthy aging and dedicated the last 10 to 12 years to advancing his expertise in metabolic health issues such as diabetes, weight loss, and inflammatory conditions. He is a co-owner of HFRC in Nedlands, Western Australia, where he has worked for nearly a decade.
